Results for "United Therapeutics"

Martine Rothblatt, CEO of United Therapeutics, sold shares worth $4.7 million in a recent transaction.

Biotechnology company United Therapeutics announced new clinical data supporting its applications for regulatory approval of two therapeutic treatments.

The CEO of United Therapeutics sold $5 million worth of company shares, leading to questions among investors about the implications of this transaction.

United Therapeutics has announced the acquisition of Thymmune Therapeutics. This strategic move aims to expand United Therapeutics' portfolio and capabilities.

Varda, a company supported by Peter Thiel, is reportedly planning to launch drugs from United Therapeutics into orbit to conduct microgravity testing.

MannKind Corporation's shares increased following the expansion of its collaboration with United Therapeutics.

United Therapeutics shares have surged following positive results from trials of its drug Tyvaso, which is being developed for the treatment of idiopathic pulmonary fibrosis.

Multiple financial institutions have updated their ratings and price targets for various companies, including Wells Fargo raising Globe Life (GL) target, Bank of America downgrading Fox (FOX), KeyBanc raising Zoom (ZM) target, H.C. Wainwright raising United Therapeutics (UTHR) target, Bernstein upgrading Newmont (NEM), analysts maintaining a hold on PepsiCo (PEP), Truist raising BILL Holdings (BILL) target, Barclays reiterating a buy on Charles Schwab (SCHW), Barclays upgrading Etsy (ETSY) and Truist raising its target, Goldman Sachs cutting Pinterest (PINS) target and RBC downgrading shares, Wells Fargo maintaining a hold on Hewlett Packard Enterprise (HPE), UBS upgrading Southwest Airlines (LUV), Stifel raising Triple Flag Precious Metals (TFPM) target, Barclays raising Phillips 66 (PSX) target, and Veritas downgrading Suncor Energy (SU).

The U.S. Food and Drug Administration (FDA) has accepted United Therapeutics' application for ralinepag, a drug intended for the treatment of Pulmonary Arterial Hypertension (PAH).

Liquidia's stock has risen after a judge criticized United Therapeutics in an ongoing patent dispute.

Leopold Aschenbrenner has disclosed new and updated positions on several stocks, showing a bearish stance on companies like Galaxy Digital, Kilroy Realty Corporation, and Lumentum Holdings. Conversely, Aschenbrenner remains bullish on ProPetro Holding Corp. and Babcock & Wilcox Enterprises, Inc., while also revealing a new bet on WhiteFiber, Inc.

Wall Street analysts have released their top research calls, with Oracle receiving an upgrade and Planet Fitness being downgraded. Analysts are also assessing whether they are bullish or bearish on Southern Company stock, reflecting shifts in sentiment for various companies.

Amcor, Equinor, Insulet, and United Therapeutics have published their earnings previews for the upcoming Q1 and Q3 2026 financial periods. These reports offer an early look at their anticipated financial performance and outlook.

Cantor Fitzgerald has raised its price target for United Therapeutics (UTHR) to $625, suggesting increased confidence in the pharmaceutical company's valuation.

United Therapeutics announced its GAAP EPS of $7.70, beating estimates, but its revenue of $790.2 million missed expectations.

The FDA is reviewing United Therapeutics' application to broaden the approved uses of its nebulized pulmonary hypertension drug, Tyvaso.

United Therapeutics has successfully completed the enrollment phase for its clinical trial focused on lung fibrosis.

An analysis considers whether United Therapeutics Corporation (UTHR) stock presents a long-term investment opportunity, particularly in the field of organ transplant innovation.

United Therapeutics announced that its drug ralinepag successfully met its primary endpoint in a study for pulmonary arterial hypertension (PAH).

United Therapeutics outlined plans to achieve a $4 billion revenue run rate by the end of 2027, driven by advancements in its ralinepag and IPF programs.

Morgan Stanley has increased its price target for Vertex Pharmaceuticals to $612 from $596, indicating a positive outlook for the company's stock.

United Therapeutics' board of directors has approved a new $2 billion share repurchase authorization and priced a $1.5 billion accelerated share repurchase (ASR) program.

Martine Rothblatt, founder and CEO of United Therapeutics, is an entrepreneur over 70 years old who is actively working towards human immortality through genetically modified organs and consciousness digitization, earning recognition from Wall Street.